Merck Patent Gmbh

Merck Patent Gesellschaft MIT Beschrankter Haftung

Francesc Mitjans

Simon Lawrence Goodman

Jaume Adan

Claudia Wilm

Diane Hahn

Jaume Piulats

Elisabet Rosell

Alfred Jonczyk

Kin-Ming Lo

Wolfgang Staehle

Guenter Hoelzemann

Wilfried Rautenberg

Mary M Bendig

Karl-August Ackermann

Helene Crassier

Elisabet Rosell-Vives

Francesc Blasco

Detlef Gussow

Keith H Ansell

A Cathrine Kettleborough

Marta Soler Riera

The invention relates to antibodies that are capable to bind the extracellular domain of integrin. Another object of the invention concerns the use of said antibodies for detecting integrins in archival formalin fixed paraffin embedded (FFPE) tissue. The invention also relates to methods for preparing monoclonal rabbit antibodies, wherein the immunogen is an insect expression culture-derived recombinant extracellular integrin domain, and another method for screening anti-integrin antibodies that discriminate between closest integrin homologues and that are especially suited for immunohistochemistry in FFPE material.

Antibodies for the detection of integrin complexes in FFPE material

The invention relates to engineered antibodies which specifically bind to integrin receptors, especially the alpha V integrin receptor subunit. The antibodies comprise the antigen binding sites (CDRs) of a known mouse anti-integrin antibody, as well as hybrid light chain variable sequences, mutated heavy chain variable sequences (Frs) and modified heavy chain constant sequences. The novel antibodies have improved immunogenic and expression properties and elicit excellent anti-angiogenic as well as anti-tumor activities in humans in monotherapy but also and above all in combination with other angiogenesis and tumor inhibiting agents.

Engineered anti-alpha V-integrin hybrid antibodies

The invention relates to compounds of formula (I) wherein R, R, R, R, R, R, R, R, R, X and X' have the designations cited in patent claim. Said compounds are inhibitors of tyrosine kinases, especially TIE-2, and Raf kinases, and can, inter alia, be used for the treatment of tumors. 

Pyridopyrimidinones

The invention relates to a novel monoclonal antibody, a hybridoma cell line producing said antibody, DNA sequences coding for said antibody, and amino acid sequences. The monoclonal antibody, a preferred embodiment of which is named 17E6, has the following properties:

Anti-.alpha.V-integrin monoclonal antibody

Anti-EGFR single-chain Fvs and anti-EGFR antibodies

Growing community of inventors

Igualada, Spain

Francesc Mitjans